Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 6/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 6/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20298564 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL20298582 | 0.98 | CHRNB2 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13733916 | 0.82 | — | — | |
| SCHEMBL6127508 | 0.77 | HSD11B1 (0.42) | CHRNB2CHRNA3CHRNA4HSD11B1HSD11B2 | |
| SCHEMBL6127513 | 0.77 | HSD11B1 (0.42) | CHRNB2CHRNA3CHRNA4HSD11B1HSD11B2 | |
| SCHEMBL19948600 | 0.73 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1404444 | 0.73 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20588744 | 0.72 | HSD11B1 (0.31) | HSD11B1HSD11B2 | |
| SCHEMBL6711523 | 0.72 | HSD11B1 (0.31) | HSD11B1HSD11B2 | |
| SCHEMBL20588745 | 0.72 | HSD11B1 (0.31) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200085791-A1 | [(PHENYLSULFONYL)OCTAHYDRO-EPIMINOISOINDOL-YL](1H-1,2,3-TRIAZOL-5-YL)METHANONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| EP-3555101-A2 | [(PHENYLSULFONYL)OCTAHYDRO-EPIMINOISOINDOL-YL](1H-1,2,3-TRIAZOL-5-YL)METHANONES | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018114677-A2 | [(PHENYLSULFONYL)OCTAHYDRO-EPIMINOISOINDOL-YL](1H-1,2,3-TRIAZOL-5-YL)METHANONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085791-A1 | [(PHENYLSULFONYL)OCTAHYDRO-EPIMINOISOINDOL-YL](1H-1,2,3-TRIAZOL-5-YL)METHANONES | PKD1, CCND2, SRD5A1 | CHRNB2 4854/4885CHRNA3 4809/4885CHRNA4 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.